TTNP
vs
S&P 500


Over the past 12 months, TTNP has underperformed S&P 500, delivering a return of -2% compared to the S&P 500's +15% growth.
Stocks Performance
TTNP vs S&P 500
Performance Gap
TTNP vs S&P 500
Performance By Year
TTNP vs S&P 500
Titan Pharmaceuticals Inc
Glance View
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. The company is headquartered in South San Francisco, California and currently employs 11 full-time employees. The firm is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.
